Evidence map›Paper›PMID 35251522›Full record

ArticleJournal of oral microbiology2022

MALDI-TOF mass spectrometry of saliva samples as a prognostic tool for COVID-19.

Lucas C Lazari, Rodrigo M Zerbinati, Livia Rosa-Fernandes, Veronica Feijoli Santiago, Klaise F Rosa, Claudia B Angeli, Gabriela Schwab, Michelle Palmieri, Dmitry J S Sarmento, Claudio R F Marinho and 10 more

Abstract read
In one paragraph

Article in Journal of oral microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Lucas C LazariGlycoProteomics Laboratory, Department of Parasitology, ICB, University of São Paulo, São Paulo, Brazil.
Rodrigo M ZerbinatiLaboratory of Virology (LIM-52-HC-FMUSP), Institute of Tropical Medicine of São Paulo, School of Medicine, University of São Paulo, São Paulo, Brazil.
Livia Rosa-FernandesGlycoProteomics Laboratory, Department of Parasitology, ICB, University of São Paulo, São Paulo, Brazil.
Veronica Feijoli SantiagoGlycoProteomics Laboratory, Department of Parasitology, ICB, University of São Paulo, São Paulo, Brazil.
Klaise F RosaGlycoProteomics Laboratory, Department of Parasitology, ICB, University of São Paulo, São Paulo, Brazil.
Claudia B AngeliGlycoProteomics Laboratory, Department of Parasitology, ICB, University of São Paulo, São Paulo, Brazil.
Gabriela SchwabLaboratory of Virology (LIM-52-HC-FMUSP), Institute of Tropical Medicine of São Paulo, School of Medicine, University of São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0003-3034-8254
Michelle PalmieriDepartment of Stomatology, School of Dentistry, University of São Paulo, São Paulo, Brazil.
Dmitry J S SarmentoDepartment of Stomatology, School of Dentistry, University of São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0001-7972-9141
Claudio R F MarinhoLaboratory of Experimental Immunoparasitology, Department of Parasitology, ICB, University of São Paulo, São Paulo, Brazil.
Janete Dias AlmeidaDepartment of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo State University, São José dos Campos, Brazil.
Kelvin ToState Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li KaShing Faculty of Medicine of the University of Hong Kong, Hong Kong, Special Administrative Region, China.ORCID https://orcid.org/0000-0002-1921-5824
Simone GiannecchiniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Carsten WrengerUnit for Drug Discovery, Department of Parasitology, ICB, University of São Paulo, São Paulo, Brazil.
Ester C SabinoInstitute of Tropical Medicine of São Paulo, School of Medicine, University of São Paulo, São Paulo, Brazil.
Herculano MartinhoCentro de Ciencias Naturais e Humanas, Universidade Federal do ABC, Santo André, Brazil.
José A L LindosoInstitute of Infectious Diseases Emílio Ribas, São Paulo, Brazil.
Edison L DurigonLaboratory of Clinical and Molecular Virology, Department of Microbiology, ICB, University of São Paulo, São Paulo, Brazil.
Paulo H Braz-SilvaLaboratory of Virology (LIM-52-HC-FMUSP), Institute of Tropical Medicine of São Paulo, School of Medicine, University of São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-1842-9521
Giuseppe PalmisanoGlycoProteomics Laboratory, Department of Parasitology, ICB, University of São Paulo, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe SARS-CoV-2 infections are still imposing a great public health challenge despite the recent developments in vaccines and therapy. Searching for diagnostic and prognostic methods that are fast, low-cost and accurate are essential for disease control and patient recovery. The MALDI-TOF mass spectrometry technique is rapid, low cost and accurate when compared to other MS methods, thus its use is already reported in the literature for various applications, including microorganism identification, diagnosis and prognosis of diseases.

methodsHere we developed a prognostic method for COVID-19 using the proteomic profile of saliva samples submitted to MALDI-TOF and machine learning algorithms to train models for COVID-19 severity assessment.

resultsWe achieved an accuracy of 88.5%, specificity of 85% and sensitivity of 91.5% for classification between mild/moderate and severe conditions. When we tested the model performance in an independent dataset, we achieved an accuracy, sensitivity and specificity of 67.18, 52.17 and 75.60% respectively.

conclusionSaliva is already reported to have high inter-sample variation; however, our results demonstrates that this approach has the potential to be a prognostic method for COVID-19. Additionally, the technology used is already available in several clinics, facilitating the implementation of the method. Further investigation using a larger dataset is necessary to consolidate the technique.

Indexed as

biomarkersprognosisproteomicsSalivaSARS-CoV-2

Identifiers

PMID35251522
PMCPMC8890567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.